Introduction
Antiphospholipid antibodies, detected either by their ability to react with the prothrombin activator complex in the lupus anticoagulant test' or to cross-react with cardiolipin in ELISA2 or radioimmunoassays,3 are known to predispose to venous and arterial thrombosis4 and recurrent fetal loss'
and to be associated with thrombocytopenia6 and haemolytic anaemia. 4 Although originally described in patients with systemic lupus erythematosus, they are known now to occur not only in other connective tissue diseases7'8 but also in patients with purely thrombotic manifestations and/or fetal loss, the so-called antiphospholipid syndrome. 9 They have also been described as a complication of a range of bacterial and viral infections'0 and may occur as a side effect of certain drugs."
There have also been sporadic reports of their association with malignancy, with the growing number of these reports suggesting that the association may not be fortuitous. The present case report of recurrent severe deep venous thrombosis in a patient with adenocarcinoma of the lung and high titre anticardiolipin antibodies adds further weight to the possibility that these antibodies may be a hitherto unrecognized factor in the development of the thrombotic problems which frequently complicate malignant disease.
Case report
A 51 year old man was admitted with a 3-day history of pain and swelling of the left calf and a one day history of left sided pleuritic chest pain. A venogram confirmed the diagnosis of a deep venous thrombosis affecting the left leg while a chest X-ray showed changes at the left base consistent with pulmonary infarction. His previous health had been good but he had smoked 25 cigarettes a day for several years. He was treated initially with intravenous heparin and then warfarin, on which he was eventually discharged.
Three weeks later he had to be readmitted with right sided pleuritic chest pain, marked breathlessness and signs now of a massive deep venous thrombosis affecting the right leg. Chest X-ray now showed bilateral basal lung shadowing consistent, once more, with pulmonary infarction. The International Normalised Ratio was therapeutic at 2.54 but tests for anticardiolipin antibodies (see later) were now positive. He was again treated with intravenous heparin for 10 days and commenced on prednisolone and azathioprine, on which he was discharged together with continuing warfarin treatment.
He had to be readmitted on 2 further occasions with recurrent deep venous thromboses of both the left and right legs, in the course of which further chest X-rays now revealed the development of a mass in the right upper lobe. Although bronchoscopy was unhelpful, a computed tomographic scan confirmed the presence of the mass together with enlarged mediastinal lymph nodes and biopsy of one of these nodes at mediastinoscopy revealed the presence of an infiltrating adenocarcinoma. He was treated with palliative deep X-ray therapy and maintained on continuing treatment with aspirin, warfarin, subcutaneous heparin injections, prednisolone and azathioprine. Despite this combined therapeutic approach, he redeveloped further massive venous thrombosis of the left leg (the fifth such event in total and the third involving the left leg) which now was complicated by the development of extensive venous gangrene which progressed, despite continuing full combined anticoagulation with intravenous heparin, aspirin and warfarin and led to his death some 7 months after the initial presentation. 
